ESR1 and breast carcinoma: In interim results reported at the 2020 San Antonio Breast Cancer Symposium (SABCS), amcenestrant monotherapy elicited antitumor activity in heavily pretreated, postmenopausal women with ER+ advanced or MBC [84] (Table 1).